Lithium

Lithium

SCHEMBL7187564

COc1cccc(OC)c1C(=O)Pc1ccc(OCC(C)C)cc1OCC(C)C.[Li]

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.38
FOS P01100 1/20 0.38
JUN P05412 1/20 0.38
SLC16A3 O15427 2/20 0.38
SLC16A1 P53985 2/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
MTNR1A P48039 3/20 0.38
MTNR1B P49286 3/20 0.38
XDH P47989 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PDE4B Q07343 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
NR1H4 Q96RI1 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7187557 0.98 FOS (0.40) MAPTFOSJUNSLC16A3SLC16A1
Lithium SCHEMBL7188985 0.93 SLC16A3 (0.36) MAPTFOSJUNSLC16A3SLC16A1
Lithium SCHEMBL7180583 0.92 KMT2A (0.41) FOSJUNXDHSMN1; SMN2
SCHEMBL7188974 0.91 FOS (0.38) MAPTFOSJUNSLC16A3SLC16A1
SCHEMBL7180578 0.89 KMT2A (0.41) FOSJUNXDHSMN1; SMN2
SCHEMBL7189092 0.87 XDH (0.39) MAPTFOSJUNSLC16A3SLC16A1
Lithium SCHEMBL7188514 0.87 FFAR1 (0.39) FOSJUNSIRT2XDHNR1H4
Lithium SCHEMBL7182340 0.87 FOS (0.39) MAPTFOSJUNSLC16A3SLC16A1
SCHEMBL7188508 0.85 FOS (0.41) FOSJUNSIRT2XDHNR1H4
SCHEMBL7182327 0.85 FOS (0.41) MAPTFOSJUNSLC16A3SLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885FOS 2702/4885JUN 4136/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885FOS 2549/4885JUN 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.